Clinical Trials Logo

Varicella clinical trials

View clinical trials related to Varicella.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02692066 Withdrawn - Varicella Clinical Trials

Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.

Start date: April 2016
Phase:
Study type: Observational

Varicella zoster virus (VZV) can lead to significant morbidity and mortality in transplant recipients. Current recommendations suggest a 4 week waiting period between vaccination and transplantation and consideration of booster immunizations if antibody response does not reach target levels. This four week waiting period can result in delayed transplant, rejection of an optimal organ, or missed opportunity to vaccinate. However, these recommendations are not evidence based. This is a prospective study to look at the immune response to varicella vaccine in children with chronic liver disease. Investigators will evaluate: 1. the time at which VZV DNA becomes undetectable in blood and saliva by PCR after vaccination in children with chronic liver disease and 2. the difference in humoral and cell mediated immune response to varicella immunization between children with chronic liver disease and healthy children.

NCT ID: NCT01738841 Withdrawn - Measles Clinical Trials

Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines

Start date: August 2013
Phase: N/A
Study type: Observational

This study will collect data on the safety of the MMRV vaccine (Priorix-Tetra™) used in routine practice in children aged 12 months to 12 years living in the Philippines.

NCT ID: NCT01626794 Withdrawn - Varicella Clinical Trials

A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)

Start date: July 2014
Phase: Phase 3
Study type: Interventional

This study will test the immunogenicity, safety, and tolerability of VARIVAX™ manufactured with the Varicella Enhanced Process (VEP) compared with the VARIVAX™ 2007 Process. The primary hypotheses being tested are 1)VARIVAX™ VEP will induce varicella-zoster virus (VZV) antibody responses that are non-inferior to those induced by VARIVAX™ 2007 process at 6 weeks after vaccination 1, and 2) VARIVAX™ VEP will induce an acceptable anti-VZV antibody response rate at 6 weeks after vaccination 1.